PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739751
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - The Clinicopathological Factors Associated with Disease Progression in Luminal A 
      Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A
      Single Center in China.
PG  - 4549-4556
AB  - BACKGROUND/AIM: This study investigated the clinicopathological factors
      associated with outcomes in patients with Luminal A breast cancer. PATIENTS AND
      METHODS: Retrospective analysis of the association of clinicopathological factors
      and breast cancer outcome in 421 patients with newly-diagnosed Luminal-A breast
      cancer that were enrolled from January 2008 to December 2014. Clinicopathological
      data were analyzed to validate the relationship with disease-free survival (DFS) 
      and overall survival (OS). Kaplan-Meier curves and log-rank tests were used to
      analyze the value of clinicopathological factors (tumor size, node status and
      lymphovascular invasion), and subsequent Cox regression analysis revealed
      significant prognostic factors. RESULTS: With a median of 61 months follow-up,
      the 5-year DFS and 5-year OS rate were 98.3% and 99.3%. Cox multivariate
      regression analysis showed that clinical anatomic stage, tumor size, status of
      lymph nodes, lymphovascular invasion and systemic treatment are strong prognostic
      factors for clinical outcome in patients with Luminal-A breast cancer. Of all 413
      patients with stage I-III breast cancer, 14 presented with metastasis (3.4%)
      during the follow up. Bone (6/14, 42.9%) was the most common site of metastasis
      followed by liver (5/14, 35.7%) and lung (4/14, 28.6%). The median survival time 
      after metastasis was 20.4 months. Of all the sites of distant metastasis, liver
      metastasis was the only factor that affected survival time after metastasis
      (chi2=6.263, p=0.012). CONCLUSION: Patients with Luminal A breast cancer have
      excellent outcomes. Liver metastasis is an important factor compressing the
      survival time after distant metastasis presents.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Ye, Jingming
AU  - Ye J
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Wang, Wenjun
AU  - Wang W
AD  - General Surgery, Third People's Hospital of Datong City, Datong, P.R. China.
FAU - Xin, Ling
AU  - Xin L
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Owen, Sioned
AU  - Owen S
AD  - Cardiff China Medical Research Collaborative (CCMRC), School of Medicine, Cardiff
      University, Cardiff, U.K.
FAU - Xu, Ling
AU  - Xu L
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Duan, Xuening
AU  - Duan X
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Cheng, Yuanjia
AU  - Cheng Y
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Pathology, Peking University First Hospital, Beijing, P.R. China.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - Pathology, Peking University First Hospital, Beijing, P.R. China.
FAU - Li, Ting
AU  - Li T
AD  - Pathology, Peking University First Hospital, Beijing, P.R. China.
FAU - Liu, Yinhua
AU  - Liu Y
AD  - Breast Disease Center, Peking University First Hospital, Beijing, P.R. China
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor
MH  - Biopsy
MH  - Breast Neoplasms/metabolism/*mortality/*pathology/therapy
MH  - China
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Tumor Burden
MH  - Young Adult
OTO - NOTNLM
OT  - Breast cancer
OT  - Luminal A
OT  - distant metastasis
OT  - molecular subtype
OT  - prognostic factor
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/02 [received]
PHST- 2017/05/18 [revised]
PHST- 2017/05/19 [accepted]
AID - 37/8/4549 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4549-4556.